C-MET抑制剂的研究进展  

RESEARCH PROGRESS OF C-MET INHIBITORS

作　　者：邵帅[1] 刘乐乐[1] 罗素琴[1] 

机构地区：[1]内蒙古医科大学药学院,内蒙古呼和浩特010110

出　　处：《内蒙古医科大学学报》2015年第2期205-210,共6页Journal of Inner Mongolia Medical University

基　　金：内蒙古自治区自然科学基金项目(MS20101206)

摘　　要：C-MET是由C-MET原癌基因编码的蛋白质,它参与了多种肿瘤的形成、转移和侵袭。C-MET抑制剂是一种非常具有挑战性的新型抗肿瘤药物,它是针对C-MET信号通路治疗肿瘤的研发产物,且基于此靶点的上市药品并不多见,。我们通过集C-MET抑制剂近年在国内的研究进展,综述其在国内的设计开发理念及活性筛选成果,探讨其在国内的未来前景。C- MET is a kind of protein that participates in a variety of tumor formation,metastasis and invasion,it is coded by C- MET proto- oncogene. C- MET inhibitor is a very challenging anticancer drugs,which is cure the cancer by cut the C- MET signaling pathway,and there is only one listed drug of C- MET inhibitor in the world. We collect all the research progress of C- MET inhibitor in recent years,review its design and development concepts and activity screening achievement,discuss its future prospects in China.

关 键 词：c-MET抑制剂 药物设计开发 研究进展 

分 类 号：R914[医药卫生—药物化学]